Impact of Clinical Pharmacists in Medication Management within the Diabetic Foot Multidisciplinary Team
Main Article Content
Keywords
Clinical pharmacist, Diabetic foot, Medication management, Multidisciplinary team
Abstract
Background: Diabetic foot complications account for about 20% of diabetes-related hospital admissions worldwide and are a leading cause of non- traumatic lower limb amputations. In Saudi Arabia, approximately 3,970 diabetes-related amputations occur each year. Clinical pharmacists can enhance medication management and patient education for those with diabetic foot disease, although evidence of their impact is limited. The purpose of this study is to assess the effectiveness and role of a Clinical Pharmacist within a Multidisciplinary Diabetic Foot Team. Method: This retrospective, single- institution study involved two patient groups: those who visited the clinical pharmacist DM-Foot clinic (Group P1) and those who did not (Group P0). Primary outcomes included a composite measure of HbA1c, LDL reduction, no re-infection, and patient adherence. Secondary outcomes comprised LDL and HbA1c differences, re-infection, major/minor amputations, 30-day readmission rates, and mortality. Results: A total of 200 patients participated, with 100 in each group. The composite outcome was achieved by 100% of patients in Group P1 compared to 87% in Group P0 (P <0.001). Group P1 exhibited significant improvements in re-infection rates (34% vs 77%, p < 0.001), HbA1c reduction (75% vs 43%, p < 0.001), LDL reduction (78% vs 14%, p < 0.001), and medication adherence (93% vs 38%, p < 0.001). No significant differences were noted in mortality, readmission rates, or amputation rates between the groups. Conclusion: Clinical pharmacists significantly contribute to the diabetic foot multidisciplinary team, improving infection prevention and medication adherence.
References
2. Rubio JA, Jiménez S, Lázaro-Martínez JL. Mortality in Patients with Diabetic Foot Ulcers: Causes, Risk Factors, and Their Association with Evolution and Severity of Ulcer. J Clin Med. 2020;9(9).
3. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark Insights. 2016;11:95-104.
4. Boye KS, Thieu VT, Lage MJ, Miller H, Paczkowski R. The Association Between Sustained HbA1c Control and Long- Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study. Adv Ther. 2022;39(5):2208-21.
5. Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better. Am J Prev Cardiol. 2024;18:100649.
6. Choi SK, Kim CK, Jo DI, Lee MC, Kim JN, Choi HG, et al. Factors Associated with a Prolonged Length of Hospital Stay in Patients with Diabetic Foot: A Single-Center Retrospective Study. Arch Plast Surg. 2017;44(6):539-44.
7. Wang X, Yuan CX, Xu B, Yu Z. Diabetic foot ulcers: Classification, risk factors and management. World J Diabetes. 2022;13(12):1049-65.
8. Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg. 2010;52(3 Suppl):17s-22s.
9. 2022. SMoHNdarR. annual report.
10. Al Odhayani AA, Al Sayed Tayel S, Al-Madi F. Foot care practices of diabetic patients in Saudi Arabia. Saudi J Biol Sci. 2017;24(7):1667-71.
11. Salih ME, Alharthi HS, Alsayed HZ, Alkhamisi AA, Alshqifi AA, Alsamiri SA, et al. Knowledge of diabetic foot prevention strategies among patients with diabetes in Al-Qunfudah Region, Saudi Arabia. International Journal of Medicine in Developing Countries. 2025;8(12):3471.
12. Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study. Saudi Pharm J. 2016;24(1):40-8.
13. Dixon DL, Khaddage S, Bhagat S, Koenig RA, Salgado TM, Baker WL. Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis. J Clin Lipidol. 2020;14(3):282-92.e4.
14. Martins RR, Silva LT, Lopes FM. Impact of medication therapy management on pharmacotherapy safety in an intensive care unit. Int J Clin Pharm. 2019;41(1):179-88.
15. Orabone AW, Do V, Cohen E. Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes. Diabetes Metab Syndr Obes. 2022;15:1911-23.
16. Musuuza J, Sutherland BL, Kurter S, Balasubramanian P, Bartels CM, Brennan MB. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. J Vasc Surg. 2020;71(4):1433-46.e3.
17. Alsuwayni B, Alhossan A. Impact of clinical pharmacist- led diabetes management clinic on health outcomes at an academic hospital in Riyadh, Saudi Arabia: A prospective cohort study. Saudi Pharm J. 2020;28(12):1756-9.
18. Kassam R, Meneilly GS. Role of the Pharmacist on a Multidisciplinary Diabetes Team. Canadian Journal of Diabetes. 2007;31(3):215-22.
19. Zhang L, Lin H, Wu W, Zhuang J, Huang L, Wang Y, et al. A meta-analysis of the impact of pharmacist interventions on clinical outcomes in patients with type-2 diabetes. Patient Educ Couns. 2024;120:108091.
20. Halalau A, Sonmez M, Uddin A, Karabon P, Scherzer Z, Keeney S. Efficacy of a pharmacist-managed diabetes clinic in high-risk diabetes patients, a randomized controlled trial - “Pharm-MD”. BMC Endocrine Disorders. 2022;22(1):69.
21. Sacks DB, Kirkman MS, Little RR. Point-of-Care HbA1c in Clinical Practice: Caveats and Considerations for Optimal Use. Diabetes Care. 2024;47(7):1104-10.
22. Tsaban G, Vidal Perez R, Krychtiuk KK, Ahrens I, Halvorsen S, Hassager C, et al. Lipid-lowering therapy after acute coronary syndromes in Europe: can we do better? European Heart Journal Acute Cardiovascular Care. 2023;12(Supplement_1).
23. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646.
24. Malaya E, Piątkowska A, Panek M, Kuna P, Kupczyk M, Kardas G. Medication adherence in allergic diseases and asthma: a literature review. Frontiers in Pharmacology. 2024;15:1488665.
25. Al-Qazaz H, Hassali MA, Shafie AA, Sulaiman SA, Sundram S, Morisky DE. The eight-item Morisky Medication Adherence Scale MMAS: translation and validation of the Malaysian version. Diabetes Res Clin Pract. 2010;90(2):216-21.
26. van Netten JJ, Bus SA, Apelqvist J, Lipsky BA, Hinchliffe RJ, Game F, et al. Definitions and criteria for diabetic foot disease. Diabetes Metab Res Rev. 2020;36 Suppl 1:e3268.
27. Alqifari SF, AlMharwal B, Aldawish R, Almokhlef SA. Impact of Pharmacist-Led Clinics on Health Outcomes of Patients With Diabetes at a Ministry of Health Diabetes & Endocrinology Center, Saudi Arabia: A Retrospective Study. Cureus. 2022;14(6):e25923.
28. Ourth HL, Hur K, Morreale AP, Cunningham F, Thakkar B, Aspinall S. Comparison of clinical pharmacy specialists and usual care in outpatient management of hyperglycemia in Veterans Affairs medical centers. Am J Health Syst Pharm. 2019;76(1):26-33.
29. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother. 2002;36(5):892-904.
30. Geber J, Parra D, Beckey NP, Korman L. Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy. 2002;22(6):738-47.
31. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy. 2000;20(11):1375-83.
32. Till LT, Voris JC, Horst JB. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Manag Care Pharm. 2003;9(3):269-73.
33. Casper EA, El Wakeel LM, Saleh MA, El-Hamamsy MH. Management of pharmacotherapy-related problems in acute coronary syndrome: Role of clinical pharmacist in cardiac rehabilitation unit. Basic Clin Pharmacol Toxicol. 2019;125(1):44-53.
34. Bagyawantha NMY, Coombes ID, Gawarammana I, Mohamed F. Impact of a clinical pharmacy intervention on medication adherence and the quality use of medicines in patients with acute coronary syndrome: a single centre nonrandomised controlled clinical trial. J Pharm Policy Pract. 2025;18(1):2468782.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.